financetom
Business
financetom
/
Business
/
Tata Power completes sale of its defence biz to Tata Advanced Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Power completes sale of its defence biz to Tata Advanced Systems
Nov 2, 2020 4:39 AM

Tata Power on Monday said it has completed the sale of its defence business to Tata Advanced Systems. Tata Advanced Systems is a wholly-owned subsidiary of Tata Sons. ”The sale was completed as per a Scheme of Arrangement, which was approved by the National Company Law Tribunal at Mumbai and Hyderabad in December 2019 and March 2020, respectively,” Tata Power said in a regulatory filing. The company said it is expected to receive an enterprise value of Rs 1,076 crore as an upfront payment.

Balance consideration is subject to completion of achieving certain milestones specified in the agreements, the company added. Tata Power said the sale of defence business is part of the company’s ongoing strategic plan to monetise its non-core assets and reduce overall leverage.

”The sale proceeds will help the company to reduce leverage and increase focus in the core business areas like renewable generation, distribution and new service-led businesses which will bring greater value for our shareholders,” Praveer Sinha, CEO and Managing Director, Tata Power said. Strategic Engineering Division (SED) is a non-core defence electronics division of the company, engaged in business of indigenous design, development, production, integration, supply and life cycle support of mission-critical defence systems.

The key products include manufacturing and assembling missile launchers, electronic warfare, night vision systems and gun systems. SED has three dedicated manufacturing units — Bangalore Electronic City, Vemagal in Karnataka (under construction) and an SEZ near Bengaluru (under construction).

First Published:Nov 2, 2020 1:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Penumbra Gets CE Mark for Computer Assisted Vacuum Thrombectomy Technologies
Penumbra Gets CE Mark for Computer Assisted Vacuum Thrombectomy Technologies
Sep 16, 2024
10:13 AM EDT, 09/16/2024 (MT Newswires) -- Penumbra (PEN) said Monday it received the CE Mark in Europe for its computer-assisted vacuum thrombectomy technologies Lightning Flash 2.0 and Lightning Bolt 7. The technologies are used to remove clots in the vascular system, the company said. Penumbra said the products will assure doctors in Europe that computer-assisted vacuum thrombectomy is a...
Mattr Signs Definitive Agreement to Sell Its Brazilian Pipe Coating Business to Vallourec For US$17.5 Million
Mattr Signs Definitive Agreement to Sell Its Brazilian Pipe Coating Business to Vallourec For US$17.5 Million
Sep 16, 2024
07:44 AM EDT, 09/16/2024 (MT Newswires) -- Mattr Corp. ( MTTRF ) on Monday entered into a definitive agreement to sell its subsidiary, Thermotite do Brazil, to Vallourec Tubular Solutions, a subsidiary of Vallourec S.A.. A statement noted Thermotite provides thermal insulation pipe coating services to the offshore oil and gas industry from its plant in Serra, Brazil and is...
SunCar Technology's H1 Net Loss Widens; Revenue Rises
SunCar Technology's H1 Net Loss Widens; Revenue Rises
Sep 16, 2024
07:42 AM EDT, 09/16/2024 (MT Newswires) -- SunCar Technology ( SDA ) reported an H1 net loss Monday of $0.67 per diluted share, wider than the $0.04 loss a year earlier. Analyst estimates were not available for comparison. Revenue for the six months ended June 30 was $203.1 million, up from $159.4 million a year earlier. ...
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Sep 16, 2024
07:59 AM EDT, 09/16/2024 (MT Newswires) -- Immatics ( IMTX ) said Monday it has ended its partnership with Bristol-Myers Squibb ( BMY ) to co-develop IMA401, targeting melanoma-associated antigen, because of current portfolio prioritization within the latter. The current partnership and license agreement, initially signed in 2021, will end on Dec. 12, the company added. Under the terms, Immatics...
Copyright 2023-2026 - www.financetom.com All Rights Reserved